Vitamin D plus calcium supplementation consistently reduced mortality among elderly patients compared with vitamin D supplementation alone, according to a study published online May 17 in the Journal of Clinical Endocrinology and Metabolism.
Vitamin D plus calcium (CaD) supplementation consistently reduced mortality among elderly patients compared with vitamin D supplementation alone, according to a study published online May 17 in the Journal of Clinical Endocrinology and Metabolism.
Using pooled data from randomized controlled trials, Lars Rejnmark, MD, PhD, of the Department of Endocrinology and Internal Medicine at Aarhus University, and colleagues performed individual patient data and trial level meta-analyses to assess mortality among patients randomized to receive either vitamin D alone or vitamin D with calcium.
The researchers found that, among 70,528 patients with a media age of 70 years, vitamin D with calcium reduced risk of mortality, whereas there was no association between vitamin D alone and mortality risk.
The patients were randomized to receive CaD (27,345), vitamin D alone (7,771), or placebo and no vitamin D (35,412). Over a 36-month follow-up period, the researchers noted that restricting the analysis to studies with CaD supplementation reduced the risk of death significantly among patients randomized to CaD (HR=0.91; 95% CI, 0.84–0.98); however, mortality was only significantly reduced in patients who received a daily dose of 10 µg of vitamin D in combination with calcium (HR=0.90; 95% CI, 0.83–0.99). The findings were supported by a trial-level meta-analysis, which demonstrated similar findings.
“Accordingly, calcium with vitamin D supplementation to elderly participants is overall not harmful to survival, and may have beneficial effects on general health,” the authors concluded. However, they noted that further study should investigate the possible interrelationships between the findings.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More